Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Cahn, Pedro; Madero, Juan Sierra; Arribas, José Ramón; Antinori, Andrea; Ortiz, Roberto; Clarke, Amanda E.; Hung, Chien-Ching; Rockstroh, Jürgen K.; Girard, Pierre-Marie; Sievers, Jörg; Man, Choy; Currie, Alexander; Underwood, Mark; Tenorio, Allan R.; Pappa, Keith; Wynne, Brian; Fettiplace, Anna; Gartland, Martin; Aboud, Michael; Smith, Kimberly; GEMINI Study Team. Lancet (London, England). 2019; 393: p.143-155. doi:10.1016/S0140-6736(18)32462-0
Article